[go: up one dir, main page]

AR108568A2 - MUTANTS OF FGF21 AND USES OF THE SAME - Google Patents

MUTANTS OF FGF21 AND USES OF THE SAME

Info

Publication number
AR108568A2
AR108568A2 ARP170101344A ARP170101344A AR108568A2 AR 108568 A2 AR108568 A2 AR 108568A2 AR P170101344 A ARP170101344 A AR P170101344A AR P170101344 A ARP170101344 A AR P170101344A AR 108568 A2 AR108568 A2 AR 108568A2
Authority
AR
Argentina
Prior art keywords
substitution
amino acid
pharmaceutical composition
fgf21
mutants
Prior art date
Application number
ARP170101344A
Other languages
Spanish (es)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR108568A2 publication Critical patent/AR108568A2/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Reivindicación 1: Un polipéptido aislado que comprende una secuencia de aminoácido de SEC ID Nº 4 y además comprende: (a) al menos una sustitución de aminoácido en la posición 180; y (b) al menos una sustitución de aminoácido seleccionada del grupo que consta de: (i) una sustitución en la posición 171; y (ii) una sustitución en la posición 98; y (c) combinaciones de las mismas. Reivindicación 11: Una composición farmacéutica que comprende el polipéptido aislado de la reivindicación 2 y un agente de formulación farmacéuticamente aceptable. Reivindicación 13: Un método de tratamiento de un trastorno metabólico que comprende la administración a un paciente humano que lo necesite de la composición farmacéutica de la reivindicación 12. Reivindicación 17: El ácido nucleico aislado de la reivindicación 16, en donde el ácido nucleico comprende SEC ID Nº 46.Claim 1: An isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 4 and further comprising: (a) at least one amino acid substitution at position 180; and (b) at least one amino acid substitution selected from the group consisting of: (i) a substitution at position 171; and (ii) a substitution in position 98; and (c) combinations thereof. Claim 11: A pharmaceutical composition comprising the isolated polypeptide of claim 2 and a pharmaceutically acceptable formulation agent. Claim 13: A method of treating a metabolic disorder comprising administration to a human patient in need of the pharmaceutical composition of claim 12. Claim 17: The isolated nucleic acid of claim 16, wherein the nucleic acid comprises SEC ID No. 46.

ARP170101344A 2009-05-05 2017-05-18 MUTANTS OF FGF21 AND USES OF THE SAME AR108568A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17573609P 2009-05-05 2009-05-05

Publications (1)

Publication Number Publication Date
AR108568A2 true AR108568A2 (en) 2018-09-05

Family

ID=52988550

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101344A AR108568A2 (en) 2009-05-05 2017-05-18 MUTANTS OF FGF21 AND USES OF THE SAME

Country Status (3)

Country Link
AR (1) AR108568A2 (en)
TN (1) TN2011000553A1 (en)
UA (1) UA107458C2 (en)

Also Published As

Publication number Publication date
TN2011000553A1 (en) 2013-05-24
UA107458C2 (en) 2015-01-12

Similar Documents

Publication Publication Date Title
AR107020A2 (en) PCSK9 VACCINE (SUBTILISINE-KEXINA TYPE 9 CONVERTASE PROTEIN)
ES2661500T3 (en) HMGB1 variants and their uses
CL2021000550A1 (en) Tumor associated peptide (tumap); nucleic acid; expression vector; recombinant host cell comprising the peptide; method of producing the peptide; pharmaceutical composition; use to prepare a drug useful for treating cancer; pharmaceutical kit (divisional application no. 201900460)
WO2015149944A3 (en) Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
MX384378B (en) THERAPEUTIC DOSAGE OF A NEUROREGULIN OR A SUBSECENCE THEREOF FOR THE TREATMENT OR PROPHYLAXIS OF HEART FAILURE.
CO6640331A2 (en) Anti-aging skin treatment
BRPI0518793A2 (en) Methods for treating, controlling or preventing an immunodeficiency disease or disorder, and for improving the immune response to an immunogen, and pharmaceutical composition.
BRPI1007379B8 (en) pharmaceutical compositions for the treatment or prevention of oral infections by e. coli
WO2014165607A3 (en) Aromatic-cationic peptide formulations, compositions and methods of use
MX2018006299A (en) Peptide analogs of alpha-melanocyte stimulating hormone.
AR112166A1 (en) THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATITIS B
RU2020121540A (en) INJECTABLE BOTULINIC TOXIN COMPOSITIONS AND METHODS OF THEIR APPLICATION WITH HIGH RESPONSE RATES AND LONG DURATION OF EFFECT
NZ599930A (en) Pharmaceutical compositions for the stimulation of stem cells.
EP4349359A3 (en) Peptide exhibiting wrinkle-improving activity and uses thereof
PH12021551656A1 (en) Pharmaceutical delivery compositions and uses thereof
RU2016137289A (en) FGF-18 COMPOUND DIAGRAM
RU2015116264A (en) COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE IN PATIENTS WITH DIABETES
PE20181332A1 (en) METHODS OF SEDATION AND PARENTERAL FORMULATION FOR USE DURING THE TREATMENT OF CRITICAL CARE
SA519410993B1 (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
AR095076A1 (en) PEPTIDES AND COMPOSITIONS FOR THE TREATMENT OF ARTICULAR DAMAGE
AR093908A1 (en) FUSION OF HUMAN AND ALBUMINE GROWTH HORMONE, FORMULATION AND USES OF THE SAME
RU2012146542A (en) METHOD FOR INHIBITING HIV REPLICATION IN MAMMAL CELLS AND IN PEOPLE
AR105752A1 (en) METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
AR093476A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ECTODERMAL DYSPLASIA
MX370397B (en) Vaccine for intrauterine disease.

Legal Events

Date Code Title Description
FB Suspension of granting procedure